Erik Ostrowski Net Worth

The estimated Net Worth of Erik Ostrowski is at least $2.81 Million dollars as of 1 February 2024. Mr. Ostrowski owns over 40,084 units of AvroBio Inc stock worth over $59,338 and over the last 6 years he sold AVRO stock worth over $0. In addition, he makes $2,753,800 as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, and Treasurer at AvroBio Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Ostrowski AVRO stock SEC Form 4 insiders trading

Erik has made over 1 trades of the AvroBio Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he exercised 40,084 units of AVRO stock worth $56,118 on 1 February 2024.

The largest trade he's ever made was exercising 40,084 units of AvroBio Inc stock on 1 February 2024 worth over $56,118. On average, Erik trades about 4,008 units every 0 days since 2019. As of 1 February 2024 he still owns at least 42,384 units of AvroBio Inc stock.

You can see the complete history of Mr. Ostrowski stock trades at the bottom of the page.

Erik Ostrowski biography

Erik Ostrowski has been appointed Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of the Company effective on January 2, 2019. From June 2014 to December 2018, Mr. Ostrowski served as the chief financial officer of Summit Therapeutics plc. Prior to that, he served as vice president of finance at Organogenesis Inc., a biotechnology company, from 2010 to 2014, and previously worked in investment banking, most recently as a director with Leerink Partners LLC. Mr. Ostrowski began his career as an accountant with Coopers & Lybrand (now PricewaterhouseCoopers) and received a B.S. in accounting and economics from Babson College and an M.B.A. from the University of Chicago Booth School of Business.

What is the salary of Erik Ostrowski?

As the Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, and Treasurer of AvroBio Inc, the total compensation of Erik Ostrowski at AvroBio Inc is $2,753,800. There are 1 executives at AvroBio Inc getting paid more, with Birgitte Volck having the highest compensation of $4,384,270.

How old is Erik Ostrowski?

Erik Ostrowski is 47, he's been the Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, and Treasurer of AvroBio Inc since 2019. There are 19 older and 1 younger executives at AvroBio Inc. The oldest executive at AvroBio Inc is Christopher Paige, 67, who is the Independent Director.

What's Erik Ostrowski's mailing address?

Erik's mailing address filed with the SEC is C/O AKEBIA THERAPEUTICS, INC, 245 FIRST ST., CAMBRIDGE, MA, 02142.

Insiders trading at AvroBio Inc

Over the last 6 years, insiders at AvroBio Inc have traded over $3,066,308 worth of AvroBio Inc stock and bought 2,395,057 units worth $31,037,133 . The most active insiders traders include Braden Michael Leonard, Bruce Booth, and Venture Fund X, L.P.Atlas V.... On average, AvroBio Inc executives and independent directors trade stock every 102 days with the average trade being worth of $206,675. The most recent stock trade was executed by Braden Michael Leonard on 13 May 2024, trading 766,635 units of AVRO stock currently worth $973,626.

What does AvroBio Inc do?

clinical stage company focused on delivering step-change cell & gene therapies targeting cancer and rare disease.

Complete history of Mr. Ostrowski stock trades at Akebia Therapeutics and AvroBio Inc

AvroBio Inc executives and stock owners

AvroBio Inc executives and other stock owners filed with the SEC include:

• Birgitte Volck,
  President - Research & Development
• Erik Ostrowski,
  Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, Treasurer
• Geoff MacKay,
  President, Chief Executive Officer, Director
• Steven Avruch,
  Secretary, Chief Legal Officer
• Geoff MacKay BSc,
  Co- Founder, Pres, CEO & Director
• Geoff MacKay,
  Co- Founder, Pres, CEO & Director
• Erik Ostrowski M.B.A.,
  CFO & Treasurer
• Steven N. Avruch J.D.,
  Chief Legal Officer & Sec.
• Philip Vickers,
  Independent Director
• Bruce Booth,
  Independent Chairman of the Board
• Christopher Paige,
  Independent Director
• Phillip Donenberg,
  Independent Director
• Annalisa Jenkins,
  Independent Director
• Ian Clark,
  Independent Director
• Gail Farfel,
  Director
• Kim Raineri,
  Chief Manufacturing and Technology Officer
• Chris Brinzey,
  IR Contact Officer
• Deanna Petersen,
  Chief Business Officer
• Dr. Essra Ridha FFPM, M.D.,
  Chief Medical Officer
• Andreas Kouri,
  Sr. VP of Global Supply Chain & External Manufacturing
• Azadeh Golipour Ph.D.,
  Chief Technology Officer
• Deanna M. Petersen MBA,
  Chief Bus. Officer
• Dr. Christopher Mason FMEDSCI, FRCS, M.D., Ph.D.,
  Chief Scientific Officer
• Dr. Christopher Mason FMEDSCI, M.D., Ph.D., FRCS,
  Chief Scientific Officer
• Deanna M. Petersen M.B.A., MBA,
  Chief Bus. Officer
• Georgette Verdin,
  Chief HR Officer
• Monique Da Silva,
  Sr. VP of Corp. Communications
• Dr. Christopher Mason,
  Chief Scientific Officer
• Kim Raineri M.B.A.,
  Chief Manufacturing & Technology Officer
• Matthew Arnold,
  Head of Operations
• Jeffrey Medin Ph.D.,
  Scientific Founder
• Venture Fund X, L.P.Atlas V...,
  
• Lifesciences Iii, L.P.Claru...,
  
• Scott Requadt,
  Director
• Vi, Llcsv Life Sciences Fun...,
  
• Katina Dorton,
  Chief Financial Officer
• Nerissa Kreher,
  Chief Medical Officer
• Venture Associates X, L.P. ...,
  10% owner
• Lifesciences Iii, L.P.Claru...,
  
• Diana Escolar,
  Chief Medical Officer
• Christopher Mason,
  Chief Scientific Officer
• Essra Ridha,
  Chief Medical Officer
• Azadeh Golipour,
  Chief Technology Officer
• Braden Michael Leonard,